不同抗血管内皮生长因子药物治疗糖尿病黄斑水肿的短期疗效分析  

Analysis of Short-term Efficacy of Different Anti-vascular Endothelial Growth Factor Drugs in the Treatment of Diabetic Macular Edema

作　　者：何霓 石鹃 李俊[3] HE Ni;SHI Juan;LI Jun(Department of OphthalmologyⅡ,Xiangxi Autonomous Prefecture People's Hospital,Xiangxi,Hunan Province,416000 China;Department of OphthalmologyⅡ,the First Affiliated Hospital of Jishou University,Xiangxi,Hunan Province,416000 China;Department of Ophthalmology Center,Lishui Central Hospital,Lishui,Zhejiang Province,)

机构地区：[1]湘西自治州人民医院眼二科,湖南湘西416000 [2]吉首大学第一附属医院眼二科,湖南湘西416000 [3]丽水市中心医院眼科中心,浙江丽水323000

出　　处：《糖尿病新世界》2023年第15期30-34,共5页Diabetes New World Magazine

基　　金：浙江省卫生健康委员会科研项目(2020RC151)。

摘　　要：目的 观察不同抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物治疗糖尿病黄斑水肿(diabetic macular edema,DME)的短期疗效。方法 回顾性分析2018年10月—2021年11月于丽水市中心医院眼科确诊的DME患者92例的临床资料,根据患者治疗药物分为3组,分别为单次玻璃体腔注射阿柏西普(IVA组,n=39)、康柏西普(IVC组,n=7)、雷珠单抗(IVR组,n=46),分别为54、9、60只眼。对比3组治疗效果。结果 对于治疗前、治疗后1 d、治疗后1月的logMAR BCVA及治疗前、治疗后1月的CFT,3组间在不同时间点比较,差异有统计学意义(F=5.341、48.049,P=0.017、P<0.001),然而不同药物类型之间比较,差异无统计学意义(F=0.789、2.028,P=0.457、0.136)。治疗前、治疗后1个月,3组的IS/OS完整性比较,差异无统计学意义(χ^(2)=3.204、2.971,P=0.200、0.233);将视力分段后比较,治疗前及治疗后1个月不同logMAR BCVA分段患眼IS/OS完整性比较,差异有统计学意义(χ^(2)=37.127、30.025,P<0.001)。结论 3种抗VEGF药物均可改善DME患眼视力,降低黄斑中心凹厚度,修复光感受器层反射光带缺损。Objective To observe the short-term efficacy of different anti-vascular endothelial growth factor(VEGF) drugs in the treatment of diabetic macular edema(DME).Methods Retrospectively analyed of the clinical data of 92 DME patients diagnosed in the ophthalmology department of Lishui Central Hospital from October 2018 to November 2021.They were divided into three groups based on the patient's treatment medication:single intravitreal injection of Arbacicept(IVA group,n=39),Conbercept(IVC group,n=7),and Rizumab(IVR group,n=46),with 54 eyes,9 eyes,and 60 eyes,respectively.Compared the treatment effects of three groups.Results For the pre-treatment,1 d post-treatment,and 1 month post-treatment logMAR BCVA and pre-treatment and 1 month post-treatment CFT,the differences were statistically significant when compared between the three groups at different time points(F=5.341,48.049,P=0.017,P<0.001).However,the differences were not statistically significant for comparisons between the different drug types(F=0.789,2.028,P=0.457,0.136).Compared IS/OS completeness among the 3 groups before and 1 month after treatment,and the difference was not statistically significant(χ^(2)=3.204,2.971,P=0.200,0.233).Segmenting the visual acuity,compared the IS/OS integrity of the affected eyes with different logMAR BCVA segments before and 1 month after treatment,and the difference was statistically significant(χ^(2)=37.127,30.025,P<0.001).Conclusion Three anti-VEGF drugs can improve the visual acuity of DME patients,reduce CFT,and repair the IS/OS defect.

关 键 词：糖尿病黄斑水肿 血管生成抑制剂 光感受器 

分 类 号：R587.1[医药卫生—内分泌]